ArticleChina CDC weekly2025
Burden and Risk Factors of Gout, Low Back Pain, Osteoarthritis, and Rheumatoid Arthritis - China, 1990-2023.
Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known on this topic?: Musculoskeletal disorders, including gout, low back pain (LBP), osteoarthritis (OA), and rheumatoid arthritis (RA), impose a substantial global health burden that intensifies with population aging. China confronts distinctive challenges stemming from rapid demographic aging and evolving occupational patterns, yet comprehensive analysis using the latest Global Burden of Disease (GBD) 2023 data to inform long-term prevention strategies remains absent. What is added by this report?: This study demonstrates that from 1990 to 2023, the disease burdens of gout, OA, and RA increased continuously, whereas the burden of LBP declined. Predictive modeling indicates these divergent trajectories - growth for gout, OA, and RA versus reduction for LBP - will persist through 2043. Additionally, substantial gender- and age-specific variations in disease burden were identified, with peak impacts concentrated in the 40-80 age range. What are the implications for public health practice?: The rising burden of these musculoskeletal diseases, concentrated in the 40-80 age group, necessitates urgent interventions aligned with "Healthy China 2030" objectives. Key priorities must include managing modifiable risk factors (body mass index, occupational ergonomics), implementing targeted screening programs for high-risk populations (males for gout, females for osteoarthritis and rheumatoid arthritis), and optimizing hierarchical diagnosis and rehabilitation systems to mitigate long-term disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.